Needham Maintains Buy on Esperion Therapeutics, Lowers Price Target to $9
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Serge Belanger has maintained a 'Buy' rating on Esperion Therapeutics (NASDAQ:ESPR) but lowered the price target from $10 to $9.
August 04, 2023 | 10:41 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Esperion Therapeutics' price target has been lowered from $10 to $9 by Needham, though the 'Buy' rating is maintained.
The news directly pertains to Esperion Therapeutics. While the lowering of the price target might be seen as a negative, the maintained 'Buy' rating indicates that the analyst still sees potential in the stock. This could lead to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100